News

Coldizin is scheduled for launch in the third quarter, in time for the ‘cough and cold season’, and Immulina is planned for launch in the fourth quarter. thin400

Alnylam Pharmaceuticals, an RNAi therapeutics company, has reported that the European Patent Office has issued a notification of intent to grant for a patent in the Tuschl I

With the CE-Marking, Biomerica said that its new one-step test can now be marketed directly to consumers through pharmacies in the EU. Biomerica’s home test, which will be

Biolex Therapeutics, a biopharmaceutical company, has started patient dosing in the Select-2 Phase IIb trial of its lead product candidate Locteron for the treatment of chronic hepatitis C.

Most recently an independent regulatory affairs consultant, Ms Rachel has also served as senior director and group head of regulatory affairs for the clinical research organization Averion International

CDA-1 and CDB-1 were co-developed by Medarex and Massachusetts Biologic Laboratories (MBL). Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize CDA-1 and

Abbott will gain access to Huya’s Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. Huya said that it has agreements in

The three purchasers were two existing investors in the company, Venrock Associates (which is affiliated with Anthony Evnin, a director of the company) and New Enterprise Associates (which

Swiss biopharmaceutical company Actelion has reported a net income of CHF102.1m, or CHF0.83 per diluted share, for the first quarter of 2009, compared to CHF44.5m, or CHF0.36 per